• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒疾病病情恶化的预测因素:高敏肌钙蛋白和D-二聚体的见解及其与右心室后负荷的相关性

Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload.

作者信息

Goudot Guillaume, Chocron Richard, Augy Jean-Loup, Gendron Nicolas, Khider Lina, Debuc Benjamin, Aissaoui Nadia, Peron Nicolas, Hauw-Berlemont Caroline, Vedie Benoit, Cheng Charles, Mohamedi Nassim, Krzisch Daphné, Philippe Aurélien, Puscas Tania, Hermann Bertrand, Brichet Julie, Juvin Philippe, Planquette Benjamin, Messas Emmanuel, Pere Hélène, Veyer David, Gaussem Pascale, Sanchez Olivier, Diehl Jean-Luc, Mirault Tristan, Smadja David M

机构信息

Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.

PARCC, INSERM, Université de Paris, Paris, France.

出版信息

Front Med (Lausanne). 2020 Nov 12;7:586307. doi: 10.3389/fmed.2020.586307. eCollection 2020.

DOI:10.3389/fmed.2020.586307
PMID:
33282891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7689153/
Abstract

Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. To explore clinical and biological parameters of COVID-19 patients with hospitalization criteria that could predict referral to intensive care unit (ICU). Analyzing the clinical and biological profiles of COVID-19 patients at admission. Among 99 consecutive patients that fulfilled criteria for hospitalization, 48 were hospitalized in the medicine department, 21 were first admitted to the medicine ward department and referred later to ICU, and 30 were directly admitted to ICU from the emergency department. At admission, patients requiring ICU were more likely to have lymphopenia, decreased SpO, a D-dimer level above 1,000 ng/mL, and a higher high-sensitivity cardiac troponin (Hs-cTnI) level. A receiver operating characteristic curve analysis identified Hs-cTnI above 9.75 pg/mL as the best predictive criteria for ICU referral [area under the curve (AUC), 86.4; 95% CI, 76.6-96.2]. This cutoff for Hs-cTnI was confirmed in univariate [odds ratio (OR), 22.8; 95% CI, 6.0-116.2] and multivariate analysis after adjustment for D-dimer level (adjusted OR, 20.85; 95% CI, 4.76-128.4). Transthoracic echocardiography parameters subsequently measured in 72 patients showed an increased right ventricular (RV) afterload correlated with Hs-cTnI ( = 0.42, = 0.010) and D-dimer ( = 0.18, = 0.047). Hs-cTnI appears to be the best relevant predictive factor for referring COVID-19 patients to ICU. This result associated with the correlation of D-dimer with RV dilatation probably reflects a myocardial injury due to an increased RV wall tension. This reinforces the hypothesis of a COVID-19-associated microvascular thrombosis inducing a higher RV afterload.

摘要

2019冠状病毒病(COVID-19)与心血管并发症和凝血障碍有关。为了探索符合住院标准的COVID-19患者的临床和生物学参数,以预测其是否会被转诊至重症监护病房(ICU)。分析COVID-19患者入院时的临床和生物学特征。在99例符合住院标准的连续患者中,48例入住内科,21例先入住内科病房,随后转诊至ICU,30例从急诊科直接入住ICU。入院时,需要入住ICU的患者更易出现淋巴细胞减少、血氧饱和度降低、D-二聚体水平高于1000 ng/mL以及更高的高敏心肌肌钙蛋白(Hs-cTnI)水平。受试者工作特征曲线分析确定Hs-cTnI高于9.75 pg/mL是ICU转诊的最佳预测标准[曲线下面积(AUC),86.4;95%可信区间(CI),76.6 - 96.2]。在对D-二聚体水平进行校正后的单因素分析[比值比(OR),22.8;95% CI,6.0 - 116.2]和多因素分析中,均证实了Hs-cTnI的这一临界值(校正后OR,20.85;95% CI,4.76 - 128.4)。随后对72例患者进行的经胸超声心动图参数测量显示,右心室(RV)后负荷增加与Hs-cTnI(r = 0.42,P = 0.010)和D-二聚体(r = 0.18,P = 0.047)相关。Hs-cTnI似乎是将COVID-19患者转诊至ICU的最佳相关预测因素。这一结果与D-二聚体与RV扩张的相关性可能反映了由于RV壁张力增加导致的心肌损伤。这强化了COVID-19相关微血管血栓形成导致更高RV后负荷的假说。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c06d/7689153/c54aaead2fd0/fmed-07-586307-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c06d/7689153/502d2c2d5a0d/fmed-07-586307-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c06d/7689153/c54aaead2fd0/fmed-07-586307-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c06d/7689153/502d2c2d5a0d/fmed-07-586307-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c06d/7689153/c54aaead2fd0/fmed-07-586307-g0002.jpg

相似文献

1
Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload.新冠病毒疾病病情恶化的预测因素:高敏肌钙蛋白和D-二聚体的见解及其与右心室后负荷的相关性
Front Med (Lausanne). 2020 Nov 12;7:586307. doi: 10.3389/fmed.2020.586307. eCollection 2020.
2
Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.在住院的 COVID-19 患者中,心脏损伤、炎症和凝血生物标志物与结局的纵向相关性。
J Mol Cell Cardiol. 2020 Oct;147:74-87. doi: 10.1016/j.yjmcc.2020.08.008. Epub 2020 Aug 20.
3
Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease.心肌损伤与新型冠状病毒肺炎:血清高敏肌钙蛋白I水平在无既往心血管疾病的新型冠状病毒肺炎患者风险分层及30天死亡率预测中的作用
Theranostics. 2020 Jul 29;10(21):9663-9673. doi: 10.7150/thno.47980. eCollection 2020.
4
Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.血管生成素-2 作为内皮细胞激活的标志物,是预测 COVID-19 患者入住重症监护病房的良好预测因子。
Angiogenesis. 2020 Nov;23(4):611-620. doi: 10.1007/s10456-020-09730-0. Epub 2020 May 27.
5
The absolute and relative changes in high-sensitivity cardiac troponin I are associated with the in-hospital mortality of patients with fulminant myocarditis.高敏心肌肌钙蛋白 I 的绝对和相对变化与暴发性心肌炎患者的院内死亡率相关。
BMC Cardiovasc Disord. 2021 Nov 30;21(1):571. doi: 10.1186/s12872-021-02386-8.
6
Prognostic value of elevated cardiac and inflammatory biomarkers in patients with severe COVID-19: a single-center, retrospective study.心脏和炎症生物标志物升高在重症 COVID-19 患者中的预后价值:一项单中心回顾性研究
Emerg Crit Care Med. 2022 Sep;2(3):122-127. doi: 10.1097/EC9.0000000000000057. Epub 2022 Sep 6.
7
Diagnostic significance of combining D-dimer with high-sensitivity cardiac troponin I for improving the diagnosis of venous thromboembolism in the emergency department.D-二聚体与高敏心肌肌钙蛋白I联合检测对提高急诊科静脉血栓栓塞症诊断的意义
Acta Biomed. 2021 Nov 3;92(5):e2021287. doi: 10.23750/abm.v92i5.9752.
8
Prediction of adverse clinical outcome in patients with acute pulmonary embolism: evaluation of high-sensitivity troponin I and quantitative CT parameters.急性肺栓塞患者不良临床结局的预测:高敏肌钙蛋白 I 和定量 CT 参数的评估。
Eur J Radiol. 2013 Mar;82(3):563-7. doi: 10.1016/j.ejrad.2012.11.009. Epub 2012 Dec 10.
9
[Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019].2019冠状病毒病患者D-二聚体浓度与炎症因子或器官功能的关系
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):559-563. doi: 10.3760/cma.j.cn121430-20200414-00518.
10
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin.采用高敏心肌肌钙蛋白 I 和 copeptin 的双标志物策略改善 COVID-19 住院患者的预后。
Clin Res Cardiol. 2022 Mar;111(3):343-354. doi: 10.1007/s00392-021-01970-4. Epub 2021 Nov 15.

引用本文的文献

1
Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.常规实验室检测对预测 SARS-CoV-2 感染者死亡和病情恶化为重症或危重症 COVID-19 的准确性。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015050. doi: 10.1002/14651858.CD015050.pub2.
2
Severe COVID-19 and its cardiopulmonary effects 6 and 18 months after hospital discharge.出院后6个月和18个月时的重症新型冠状病毒肺炎及其心肺影响
Front Cardiovasc Med. 2024 Mar 5;11:1366269. doi: 10.3389/fcvm.2024.1366269. eCollection 2024.
3
Association between echocardiographic features and inflammatory biomarkers with clinical outcomes in COVID-19 patients in Saudi Arabia.

本文引用的文献

1
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
2
Cardiac Injury Patterns and Inpatient Outcomes Among Patients Admitted With COVID-19.COVID-19 患者入院后的心脏损伤模式和住院结局。
Am J Cardiol. 2020 Oct 15;133:154-161. doi: 10.1016/j.amjcard.2020.07.040. Epub 2020 Jul 24.
3
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19.
沙特阿拉伯COVID-19患者超声心动图特征及炎症生物标志物与临床结局的关联
Front Cardiovasc Med. 2023 May 26;10:1134601. doi: 10.3389/fcvm.2023.1134601. eCollection 2023.
4
COVID-19 associated coagulopathy: A bibliometric investigation.新型冠状病毒肺炎相关凝血病:一项文献计量学研究
Heliyon. 2023 Jun;9(6):e16507. doi: 10.1016/j.heliyon.2023.e16507. Epub 2023 May 25.
5
Fibrin monomers evaluation during hospitalization for COVID-19 is a predictive marker of in-hospital mortality.新冠病毒疾病住院期间纤维蛋白单体评估是院内死亡率的预测指标。
Front Cardiovasc Med. 2023 Mar 30;10:1001530. doi: 10.3389/fcvm.2023.1001530. eCollection 2023.
6
Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19.HLA I 类基因型与糖尿病合并 COVID-19 患者死亡率的相关性研究。
Dokl Biochem Biophys. 2022 Dec;507(1):289-293. doi: 10.1134/S1607672922060114. Epub 2023 Feb 14.
7
Inflammation and vascular remodeling in COVID-19 hearts.新型冠状病毒肺炎心脏中的炎症和血管重构。
Angiogenesis. 2023 May;26(2):233-248. doi: 10.1007/s10456-022-09860-7. Epub 2022 Nov 12.
8
D-dimer, BNP/NT-pro-BNP, and creatinine are reliable decision-making biomarkers in life-sustaining therapies withholding and withdrawing during COVID-19 outbreak.在新冠疫情期间,D-二聚体、脑钠肽/氨基末端脑钠肽前体以及肌酐是在维持生命治疗的 withholding 和 withdrawing 过程中可靠的决策生物标志物。 (注:这里“withholding”和“withdrawing”在医学语境中可能有特定含义,比如“ withholding”可能是指暂不给予某种治疗措施,“withdrawing”可能是指撤掉已有的治疗措施等,结合语境推测大致意思,准确理解还需结合更专业背景知识)
Front Cardiovasc Med. 2022 Sep 6;9:935333. doi: 10.3389/fcvm.2022.935333. eCollection 2022.
9
Increased Circulating CD62E Endothelial Extracellular Vesicles Predict Severity and in- Hospital Mortality of COVID-19 Patients.循环 CD62E 内皮细胞外囊泡增加可预测 COVID-19 患者的严重程度和住院死亡率。
Stem Cell Rev Rep. 2023 Jan;19(1):114-119. doi: 10.1007/s12015-022-10446-5. Epub 2022 Aug 18.
10
Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19.α1-抗胰蛋白酶与白细胞介素 6 失衡与 COVID-19 住院期间的死亡率和血栓形成有关。
Biochimie. 2022 Nov;202:206-211. doi: 10.1016/j.biochi.2022.07.012. Epub 2022 Aug 8.
早期检测升高的心脏生物标志物以优化 COVID-19 患者的风险分层。
Heart. 2020 Oct;106(19):1512-1518. doi: 10.1136/heartjnl-2020-317322. Epub 2020 Aug 14.
4
Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study.中国武汉新冠肺炎的临床结局:一项大型队列研究。
Ann Intensive Care. 2020 Jul 31;10(1):99. doi: 10.1186/s13613-020-00706-3.
5
Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019.新型冠状病毒病所致急性呼吸窘迫综合征患者的肺复张潜力和通气-灌注不匹配。
Crit Care Med. 2020 Aug;48(8):1129-1134. doi: 10.1097/CCM.0000000000004386.
6
The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation.COVID-19 死亡患者肺部病变的演变:一项临床关联的尸检研究。
Virchows Arch. 2020 Sep;477(3):349-357. doi: 10.1007/s00428-020-02881-x. Epub 2020 Jun 30.
7
Curative anticoagulation prevents endothelial lesion in COVID-19 patients.抗凝治疗可预防 COVID-19 患者的内皮损伤。
J Thromb Haemost. 2020 Sep;18(9):2391-2399. doi: 10.1111/jth.14968. Epub 2020 Jul 30.
8
Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis.心脏生物标志物和合并症与 COVID-19 患者死亡率、严重程度和心脏损伤增加的关系:荟萃回归和决策树分析。
J Med Virol. 2020 Nov;92(11):2473-2488. doi: 10.1002/jmv.26166. Epub 2020 Jul 6.
9
Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection.COVID-19 感染住院患者心肌损伤的患病率和影响。
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546. doi: 10.1016/j.jacc.2020.06.007. Epub 2020 Jun 8.
10
Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study.新型冠状病毒肺炎的心脏表现谱:一项系统超声心动图研究。
Circulation. 2020 Jul 28;142(4):342-353. doi: 10.1161/CIRCULATIONAHA.120.047971. Epub 2020 May 29.